175 related articles for article (PubMed ID: 27600044)
1. Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.
Desta Z; Metzger IF; Thong N; Lu JB; Callaghan JT; Skaar TC; Flockhart DA; Galinsky RE
Antimicrob Agents Chemother; 2016 Nov; 60(11):6813-6822. PubMed ID: 27600044
[TBL] [Abstract][Full Text] [Related]
2. Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.
Cho DY; Shen JH; Lemler SM; Skaar TC; Li L; Blievernicht J; Zanger UM; Kim KB; Shin JG; Flockhart DA; Desta Z
Drug Metab Pharmacokinet; 2016 Apr; 31(2):107-16. PubMed ID: 27053325
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.
Wang PF; Neiner A; Kharasch ED
Drug Metab Dispos; 2019 Oct; 47(10):1195-1205. PubMed ID: 31324697
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.
Robarge JD; Metzger IF; Lu J; Thong N; Skaar TC; Desta Z; Bies RR
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799204
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
[TBL] [Abstract][Full Text] [Related]
6. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
[TBL] [Abstract][Full Text] [Related]
7. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.
Ward BA; Gorski JC; Jones DR; Hall SD; Flockhart DA; Desta Z
J Pharmacol Exp Ther; 2003 Jul; 306(1):287-300. PubMed ID: 12676886
[TBL] [Abstract][Full Text] [Related]
8. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.
Ogburn ET; Jones DR; Masters AR; Xu C; Guo Y; Desta Z
Drug Metab Dispos; 2010 Jul; 38(7):1218-29. PubMed ID: 20335270
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
[TBL] [Abstract][Full Text] [Related]
10. Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index.
Jiang F; Desta Z; Shon JH; Yeo CW; Kim HS; Liu KH; Bae SK; Lee SS; Flockhart DA; Shin JG
Br J Clin Pharmacol; 2013 Jan; 75(1):244-53. PubMed ID: 22554354
[TBL] [Abstract][Full Text] [Related]
11. CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers.
Metzger IF; Dave N; Kreutz Y; Lu JBL; Galinsky RE; Desta Z
Clin Transl Sci; 2019 Nov; 12(6):657-666. PubMed ID: 31339646
[TBL] [Abstract][Full Text] [Related]
12. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.
Ngaimisi E; Mugusi S; Minzi OM; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Burhenne J; Aklillu E
Clin Pharmacol Ther; 2010 Nov; 88(5):676-84. PubMed ID: 20881953
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers.
Zubiaur P; Saiz-Rodríguez M; Ochoa D; Belmonte C; Román M; Mejía G; Martín-Vilchez S; Abad-Santos F
Pharmacogenomics J; 2020 Apr; 20(2):235-245. PubMed ID: 31628422
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.
Abdelhady AM; Shugg T; Thong N; Lu JB; Kreutz Y; Jaynes HA; Robarge JD; Tisdale JE; Desta Z; Overholser BR
J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1206-1213. PubMed ID: 27333947
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
Liu P; Foster G; LaBadie RR; Gutierrez MJ; Sharma A
J Clin Pharmacol; 2008 Jan; 48(1):73-84. PubMed ID: 18025525
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.
Nirogi R; Palacharla RC; Mohammed AR; Manoharan A; Ponnamaneni RK; Bhyrapuneni G
Chem Biol Interact; 2015 Mar; 230():9-20. PubMed ID: 25656918
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation.
Watanabe T; Saito T; Rico EMG; Hishinuma E; Kumondai M; Maekawa M; Oda A; Saigusa D; Saito S; Yasuda J; Nagasaki M; Minegishi N; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
Biochem Pharmacol; 2018 Oct; 156():420-430. PubMed ID: 30201214
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.
Abdelhady AM; Desta Z; Jiang F; Yeo CW; Shin JG; Overholser BR
J Clin Pharmacol; 2014 Jan; 54(1):87-96. PubMed ID: 24142869
[TBL] [Abstract][Full Text] [Related]
20. Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.
Court MH; Almutairi FE; Greenblatt DJ; Hazarika S; Sheng H; Klein K; Zanger UM; Bourgea J; Patten CJ; Kwara A
Antimicrob Agents Chemother; 2014 Jul; 58(7):4145-52. PubMed ID: 24820076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
